Plus Therapeutics
PSTV
PSTV was delisted on the 31st of July, 2026.
10 hedge funds and large institutions have $768K invested in Plus Therapeutics in 2020 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 3 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
0% less ownership
Funds ownership: 0.02% → 0.02% (-0%)
9% less funds holding
Funds holding: 11 → 10 (-1)
12% less capital invested
Capital invested by funds: $875K → $768K (-$107K)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$162K |
| 2 |
Two Sigma Investments
New York
|
+$91.5K |
| 3 |
Two Sigma Advisers
New York
|
+$56.4K |
| 4 |
Creative Planning
Overland Park,
Kansas
|
+$31.6K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$13.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$166K |
| 2 |
Bank of New York Mellon
New York
|
-$79K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$23.1K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$23K |
| 5 |
VF
Virtu Financial
New York
|
-$7.7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
BlackRock
New York
| $244K | – | – | – |
|
|
2
Renaissance Technologies
New York
| $214K | +$162K | +190 | +204% |
|
|
3
Two Sigma Investments
New York
| $114K | +$91.5K | +107 | +243% |
|
|
4
Two Sigma Advisers
New York
| $50K | +$56.4K | +66 | New |
|
|
5
Vanguard Group
Malvern,
Pennsylvania
| $43K | +$13.7K | +16 | +39% |
|
|
VF
6
Virtu Financial
New York
| $37K | -$7.7K | -9 | -16% |
|
|
7
Creative Planning
Overland Park,
Kansas
| $28K | +$31.6K | +37 | New |
|
|
8
Citadel Advisors
Miami,
Florida
| $25K | -$23.1K | -27 | -45% |
|
9
Osaic Holdings
Scottsdale,
Arizona
| $12K | +$5.99K | +7 | +78% |
|
|
TRCT
10
Tower Research Capital (TRC)
New York
| $1K | -$1.71K | -2 | -67% |
|
|
FP
11
Financial Perspectives
Minneapolis,
Minnesota
| $2 | – | – | – |
|
|
12
Goldman Sachs
New York
| – | -$166K | -173 | Closed |
|
|
13
Bank of New York Mellon
New York
| – | -$79K | -83 | Closed |
|
|
14
Acadian Asset Management
Boston,
Massachusetts
| – | -$23K | -24 | Closed |
|
PSTV Hedge Fund Activity: Q4 2020 in Review
10 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Plus Therapeutics (PSTV) for Q4 2020, worth a combined $768K — down 12% from $875K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of PSTV and 2 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 4 added.
The largest buyer was Renaissance Technologies, adding an estimated $162K. The largest seller was Goldman Sachs, exiting entirely with an estimated $166K sold.
- 10 institutional investors held Plus Therapeutics (PSTV) as of Q4 2020, down from 11 in Q3 2020.
- Funds reported $768K of Plus Therapeutics stock for Q4 2020, down 12% quarter-over-quarter.
- 2 funds opened new Plus Therapeutics positions in Q4 2020 and 3 closed out, a net change of -1 holder.
- The largest Plus Therapeutics buyer in Q4 2020 was Renaissance Technologies, an estimated $162K added.
- The largest Plus Therapeutics seller in Q4 2020 was Goldman Sachs, an estimated $166K sold.
Based on aggregated 13F filings for Q4 2020.